Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 301-310

  Yadegarfar, G ^a,b   Friend, L ^a,b   Jones, L ^c   Plum, L M ^d   Ardill, J ^e   Taal, B ^f   Larsson, G ^g   Jeziorski, K ^h   Kwekkeboom, D ⁱ   Ramage, J K ^j,k  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UPPSALA UNIVERSITY   (Sweden)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

more..

Author keywords

Carcinoid; Neuroendocrine; Patient reported outcome measure; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; CONSTIPATION; DYSPNEA; FEMALE; GASTROINTESTINAL NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SLEEP DISORDER; VALIDATION STUDY; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; DATA COLLECTION; FEMALE; GASTROINTESTINAL NEOPLASMS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NEUROSECRETORY SYSTEMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84873729925     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.560     Document Type: Article

References (42)

1. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK (2009) Midgut neuroendocrine tumours with liver metastases: Results of the UKINETS study. Endocr Relat Cancer 16(3): 885-894.
2. Bonett DG (2002) Sample size requirements for testing and estimating coefficient alpha. J Educ Behav Stat 27: 335-340. (Pubitemid 36385299)
3. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11(3): 570-579. (Pubitemid 23071057)
4. Cronbach LJ, Warrington WG (1951) Time-limit tests: Estimating their reliability and degree of speeding. Psychometrika 16(2): 167-188.
5. Cull A, Sprangers M, Bjordal K, Aaronson N, West K, Bottomley A (2002) EORTC Quality of Life Group translation procedure. Available at: http://groupseortcbe/qol/downloads/200202translation-manualpdf.
6. Davies AH, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK (2006) Development of a disease-specific Quality of Life Questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 42(4): 477-484. (Pubitemid 43227926)
7. Davies AHG, Mason T, StangoüAJ. al e (2003) Neuroendocrine tumours of the gut, liver and pancreas: Overall survival in a large cohort. Gut 52: A38.
8. Davis Z, Moertel CG, McIlrath DC (1973) The malignant carcinoid syndrome. Surg Gynecol Obstet 137(4): 637-644.
9. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A (2007) Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18(4): 775-781. (Pubitemid 46523284)
10. Ellis L, Shale MJ, Coleman MP (2010) Carcinoid tumors of the gastrointestinal tract: Trends in incidence in England since 1971. Am J Gastroenterol 105(12): 2563-2569.
11. Fayers PM (2004) Quality-of-life measurement in clinical trials-the impact of causal variables. J Biopharm Stat 14(1): 155-176. (Pubitemid 38294758)
12. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQC30 Scoring Manual. 3rd edn (European Organisation for Research and Treatment of Cancer: Brussels.
13. Hays RD, Havashi T, Carson S, Ware JE (1988) User's Guide for the Multitrait Analysis Program (MAP). Rand: Santa Monica, Canada.
14. Hemminki K, Li X (2001a) Familial carcinoid tumors and subsequent cancers: A nation-wide epidemiologic study from Sweden. Int J Cancer 94(3): 444-448. (Pubitemid 32906079)
15. Hemminki K, Li X (2001b) Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 92(8): 2204-2210.
16. Jacobsen MB, Hanssen LE (1995) Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 237(3): 269-275.
17. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K (1997) Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8(7): 685-690. (Pubitemid 27372168)
18. Kavadas V, Blazeby JM, Conroy T, Sezer O, Holzner B, Koller M, Buckels J (2003) Development of an EORTC disease-specific Quality of Life Questionnaire for use in patients with liver metastases from colorectal cancer. Eur J Cancer 39(9): 1259-1263. (Pubitemid 36579197)
19. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS (1998) Carcinoids of unknown origin: Comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 124(6): 1063-1070. (Pubitemid 28555194)
20. Larsson G, Haglund K, Von Essen L (2003) Distress, quality of life and strategies to 'keep a good mood' in patients with carcinoid tumours: Patient and staff perceptions. Eur J Cancer Care (Engl) 12(1): 46-57. (Pubitemid 37255606)
21. Larsson G, Sjoden PO, Oberg K, Eriksson B, von Essen L (2001) Healthrelated quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol 40(7): 825-831. (Pubitemid 34081662)
22. Larsson G, Sjoden PO, Oberg K, von Essen L (1999a) Importance- satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann Oncol 10(11): 1321-1327.
23. Larsson G, von Essen L, Sjoden PO (1999b) Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol 38(4): 481-490. (Pubitemid 29305724)
24. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97(4): 934-959. (Pubitemid 36173145)
25. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1): 61-72.
26. Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79(4): 813-829. (Pubitemid 27076348)
27. Nave H, Mossinger E, Feist H, Lang H, Raab H (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years. Surgery 129(2): 170-175.
28. Nunnally J, Bernstein I (1994) Psychometric Theory. 3rd edition ed (McGraw-Hill: New York.
29. O'Toole D, Ducreux M, Bommelaer G, WemeaüJL, Bouche O, Catus F, Blumberg J, Ruszniewski P (2000) Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88(4): 770-776. (Pubitemid 30091095)
30. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1): 6-32.
31. Ramage JK, Davies AH (2003) Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer 10(4): 483-486. (Pubitemid 38094885)
32. Shebani KO, SoubaWW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Endocr Relat Cancer 229(6): 815-821; discussion 822-823.
33. Snow ND, Liddle RA (1995) Neuroendocrine tumors. In Gastrointestinal Cancers: Biology, Diagnosis and Therapy, Rustigi AK (ed), p 585, Lippincott-Raven: Philadelphia.
34. Soga J (1998) Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: A comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res 17(1): 3-12.
35. Soreide JA, van Heerden JA, Thompson GB, Schleck C, Ilstrup DM, Churchward M (2000) Gastrointestinal carcinoid tumors: Long-term prognosis for surgically treated patients. World J Surg 24(11): 1431-1436.
36. Tabachnik BJ, Fidel LS (1993) Using Multivariate Statistics. Harper and Row: London.
37. Vinik E, Carlton CA, Silva MP, Vinik AI (2009) Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas 38(3): E87-e95.
38. Walter SD, Eliasziw M, Donner A (1988) Sample size and optimal designs for reliability studies. Stat Med 17: 101-110.
39. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T, Ahlman H (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20(7): 892-899discussion 899. (Pubitemid 26281920)
40. Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE (2002) Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. Int J Epidemiol 31(1): 168-174. (Pubitemid 34284922)
41. Wheeler MH, Maddox P, Maddineni S, Jordan S, Amer K, Butchart E (2000) Surgical treatment of carcinoid tumours. Przegl Lek 57(Suppl 5): 95-97.
42. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG, Oberg KE (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17(4): 1111.